STOCK TITAN

Alpine Immune Sc - ALPN STOCK NEWS

Welcome to our dedicated page for Alpine Immune Sc news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sc stock.

Alpine Immune Sciences (ALPN) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer, autoimmune diseases, and inflammatory conditions. This page provides investors and researchers with timely updates on ALPN's scientific advancements, strategic partnerships, and clinical milestones.

Access verified press releases and news articles covering key developments, including clinical trial progress, regulatory updates, and collaborative research initiatives. Our curated collection ensures transparent access to essential information for evaluating ALPN's position in the immunotherapy landscape.

Explore updates on ALPN's recombinant protein-based therapies and immune synapse modulation approaches. Content spans preclinical breakthroughs, Phase 1-3 trial results, licensing agreements, and financial disclosures – all critical for understanding the company's trajectory.

Bookmark this page for streamlined tracking of ALPN's progress in developing targeted treatments for complex disorders. Regular updates provide insights into the company's scientific rigor and its potential to address unmet medical challenges through immunological innovation.

Rhea-AI Summary

Frazier Life Sciences (FLS) has appointed Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. Dr. Gold, previously Co-Founder, CEO, and Executive Chairman of Alpine Immune Sciences (ALPN), led the company from inception to its recent $4.9 billion acquisition by Vertex Pharmaceuticals in May 2024. He also founded Alpine Biosciences, which was sold to Cascadian Therapeutics in 2014.

Dr. Peng joins FLS from his role as President and Head of Research and Development at Alpine Immune Sciences, where he led the development of multiple drug candidates, including povetacicept. His experience includes leadership positions at Seagen, Roche, and Stemcentrx. Both appointments aim to strengthen FLS's capabilities in identifying and developing breakthrough biopharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Alpine Immune Sciences reported its financial results for the first quarter of 2024, with a cash position of $362.4 million. Vertex Pharmaceuticals will acquire Alpine for $65 per share, expected to close in Q2 2024. Collaboration revenue decreased to $7.0 million, with an increase in research and development expenses to $22.5 million. Net loss for Q1 2024 was $17.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) shares updated clinical data for povetacicept in IgA nephropathy, showing UPCR reductions of over 60% at 36 weeks, remission, resolution of hematuria, and stable renal function. Successful end of phase 2 meeting with FDA supports advancement to phase 3 study. Key biomarkers Gd-IgA1 and Gd-IgA1/C3 ratios significantly reduced. Monthly dosing well-tolerated with no severe infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
Rhea-AI Summary
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion: A Strategic Move in Immunotherapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion in Cash, Focusing on Povetacicept for IgA Nephropathy Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) to present updated clinical data for povetacicept in IgA nephropathy patients at the World Congress of Nephrology. Investor event scheduled on April 15th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences clinical trial
Rhea-AI Summary
Alpine Immune Sciences presents promising translational data for povetacicept (ALPN-303) at SLEuro 14th European Lupus Meeting. Povetacicept demonstrates superior disease activity reduction in a lupus mouse model compared to WT TACI-Ig or B cell depletion. It shows increased distribution to disease-related organs. A phase 2 study in SLE (DENALI) is planned for 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
none
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) to participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. Remy Durand, Chief Business Officer, to join fireside chat. Investor meetings scheduled. Webcasts and replays available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
-
Rhea-AI Summary
Alpine Immune Sciences, Inc. reports positive clinical data on povetacicept in IgA nephropathy and systemic lupus erythematosus. The company plans pivotal phase 3 trials for IgAN and phase 2 trials for SLE. Financially, Alpine saw a significant increase in collaboration revenue and a strong cash position, enough to fund operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.63%
Tags
Rhea-AI Summary
Alpine Immune Sciences, Inc. (ALPN) will release its fourth quarter and full year 2023 financial results on March 18, 2024. The company focuses on developing treatments for autoimmune and inflammatory diseases. A conference call and webcast will be held on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences earnings
Alpine Immune Sc

Nasdaq:ALPN

ALPN Rankings

ALPN Stock Data

4.46B
62.73M
4.65%
99.47%
5.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE